---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-053295"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:52:23.500935+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients

## Summary
- Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.
- SYMON-II pivotal study enrollment at ~680 patients toward target of 750.
- Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.
- Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities.

## SEC filing metadata
- accession: 0001213900-26-053295
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/0001213900-26-053295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/ea0289580-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-053295
- JSON: https://secwatch.observer/filing/0001213900-26-053295.json
- Plain text: https://secwatch.observer/filing/0001213900-26-053295.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported fiscal quarter ended March 31, 2026 results: net income approximately $1.9 million.
  - Period: fiscal quarter ended March 31, 2026
  - Net income: approximately $1.9 million
  - Result: reported results
  source text: As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. The Company reported a net loss of approximately $1.9 million for the first quarter of 2026, compared to approximately $1.9 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/0001213900-26-053295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.